⚡ZurzAI.com⚡
AI Start Ups Your Should Know
Avicenna.AI
Avicenna.AI specializes in artificial intelligence solutions for medical imaging applications, focusing on radiology.
Avicenna.AI, established in 2018 through a collaboration between Cyril Di Grandi and Dr. Peter Chang, focuses on creating artificial intelligence solutions aimed at enhancing radiology practice, particularly in emergency and incidental findings on CT scans. Their technology aims to automate repetitive tasks in radiology, thus allowing medical professionals to devote more time to critical cases and facilitating more rapid and precise diagnoses.
Core Products and Solutions:
-
CINA-ICH: Targets intracranial hemorrhage detection on non-contrast CT scans, aiming to reduce turnaround times for detecting head trauma injuries and hemorrhagic strokes.
-
CINA-LVO: Focuses on detecting large vessel occlusions, a primary cause of ischemic strokes. This tool is prioritized on radiologist worklists for more urgent responses.
-
CINA-ASPECTS: An AI-based tool that quantifies strokes using the ASPECT score, providing fast, consistent assessment and aiding in the evaluation and treatment of ischemic strokes.
-
CINA-PE and CINA-iPE: These tools detect pulmonary embolisms, including incidental findings during chest CT scans, responding to the complexity of diagnosing pulmonary embolism.
-
CINA-AD: Detects aortic dissection, a severe cardiovascular issue, ensuring patients receive urgent medical intervention.
-
CINA-VCF and CINA-CSpine: Detect vertebral compression fractures and cervical spine fractures on CT scans, enabling early intervention and improving patient management.
Value Proposition:
- Reduced Interpretation Time: AI tools are designed to quickly detect diseases, delivering precise results and allowing healthcare workers to intervene promptly.
- Optimized Patient Management: Healthcare providers can streamline and prioritize patient workflows, effectively managing resources and improving patient outcomes.
- Enhanced Radiology Workflow: By handling routine tasks, AI solutions allow radiologists to manage greater workloads, reducing case turnaround times and increasing productivity.
Milestones and Developments: Since its inception, Avicenna.AI has made significant strides in securing funding, launching several AI-powered products for radiology, and obtaining necessary regulatory clearances including FDA approvals and CE markings for various solutions. As of 2023, the company has secured nearly $10 million in Series A funding.
Academic and Clinical Contributions: Avicenna.AI emphasizes the validation of their solutions through clinical studies and publications, proving the efficacy and accuracy of their AI tools in real-world scenarios. Their research is presented in various scientific journals and conferences.
Global Presence and Collaborations: The company partners with various healthcare and AI technology providers to enhance the reach and implementation of their solutions across hospitals and countries, focusing on collaboration as a key strategy to extend their AI solutions to a global audience.
Overall, Avicenna.AI aims to revolutionize radiology with AI-driven tools that expedite and enhance the diagnostic process, ensuring timely patient care and improving healthcare delivery efficiency across the globe.